Rigel Pharmaceuticals Inc. (New) financials
$48.89−0.95%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $78.7M | $58.8M | $69.8M | $69.5M | $101.7M | $53.3M | $57.6M | $55.3M | $36.8M | $29.5M | $35.8M | $28.1M |
| Gross profit | $70.2M | $54.2M | $63.8M | $64.7M | $97.2M | $48.9M | $51.8M | $47.3M | $34.0M | $27.5M | $32.0M | $26.9M |
| Gross margin | 89.2% | 92.2% | 91.5% | 93.2% | 95.6% | 91.7% | 89.9% | 85.5% | 92.4% | 93.1% | 89.4% | 95.5% |
| Operating income | $23.6M | $11.9M | $23.2M | $28.4M | $61.1M | $12.8M | $16.7M | $14.1M | $447.0K | -$7.0M | $2.0M | -$4.5M |
| Net income | $17.3M | $8.7M | $268.1M | $27.9M | $59.6M | $11.4M | $14.3M | $12.4M | -$1.0M | -$8.2M | $737.0K | -$5.7M |
| Net margin | 22.0% | 14.7% | 384.0% | 40.2% | 58.6% | 21.5% | 24.9% | 22.5% | −2.8% | −27.9% | 2.1% | −20.2% |
| Diluted EPS | $0.88 | $0.44 | $13.49 | $1.46 | $3.28 | $0.63 | $0.80 | $0.70 | $-0.06 | $-0.47 | $0.02 | $-0.33 |
| EBITDA | $24.4M | $12.5M | $23.8M | $29.0M | $61.7M | $13.4M | $17.3M | $14.7M | $1.1M | -$6.6M | $2.3M | -$4.2M |
| Operating cash flow | $30.7M | $2.7M | $22.0M | $24.0M | $30.5M | -$893.0K | $14.5M | $21.7M | $302.0K | -$5.0M | -$6.2M | -$1.4M |
| Free cash flow | $30.7M | $2.7M | $22.0M | $24.0M | $30.5M | -$893.0K | $14.5M | $21.7M | $302.0K | -$5.0M | -$6.2M | -$1.4M |
| Diluted shares | 19.6M | 19.7M | 19.9M | 19.2M | 18.2M | 18.2M | 18.0M | 17.6M | 17.5M | 17.5M | 48.8M | 17.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $60.8M | $24.4M | $40.6M | $48.5M | $53.4M | $45.7M |
| Short-term investments | $34.5M | $122.3M | $114.4M | $88.6M | $55.0M | $31.4M |
| Total debt | $39.2M | $44.9M | $52.3M | $59.7M | $59.8M | $59.7M |
| Total assets | $521.1M | $504.6M | $513.6M | $242.5M | $206.7M | $176.0M |
| Total liabilities | $95.6M | $104.7M | $122.1M | $124.9M | $124.8M | $157.4M |
| Shareholders' equity | $425.4M | $399.9M | $391.5M | $117.6M | $81.9M | $18.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology